Our Pipeline
Extensive, late-stage radiopharmaceutical pipeline.
Our core pipeline spans urologic oncology (prostate and kidney), neuro-oncology (glioma), and other solid tumors and hematologic-oncology (blood). Across these programs, extensive clinical data supports both efficacy potential and an acceptable safety profile.We focus on validated targets well suited to targeted radiation, leveraging imaging to personalise treatment and strengthen efficacy.
Therapeutic pipeline
Swipe to see more
Asset
Targeting agent
Isotope
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
TLX591-Tx
mAb
177Lu
Target/indication
PSMA1/mCRPC2
TLX250-Tx
mAb
177Lu
CAIX4/ccRCC5, CAIX-expressing tumors
TLX597-Tx
SM
177Lu
PSMA1/mHSPC3
TLX592-Tx
mAb
225Ac (α)
PSMA1/mCRPC2
TLX090-Tx
SM
153Sm
Bone mets6/palliation
TLX252-Tx
mAb
225Ac (α)
CAIX4/ccRCC5, CAIX-expressing tumors
TLX101-Tx
SM
131I
LAT17/GBM8
TLX102-Tx
SM
211At (α)
LAT17/GBM8, LMD9
TLX66-Tx
mAb
90Y
CD6610/AML11
TLX400-Tx
SM
177Lu
FAP12/pan-tumor
TLX300-Tx
mAb
Undisclosed
PDGFRα13/STS14
Precision medicine portfolio
Swipe to see more
Asset
Targeting agent
Isotope
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Illuccix®
SM
68Ga
Target/indication
PSMA1/Staging
Gozellix®
SM
68Ga
PSMA1/mCRPC2
TLX593-Px
SM
68Ga/18F
(AIFluor™)
PSMA1/mCRPC2
TLX250-Px Zircaix®
mAb
89Zr
CAIX4/ccRCC5
TLX101-Px Pixclara®
SM
18F
LAT17/Glioma
TLX66-Px Scintimun®
SM
18F
CD6610/Osteomyelitis
Explore our portfolio
in detail
FOOTNOTES
- PSMA – prostate-specific membrane antigen
- mCRPC – metastatic castration-resistant prostate cancer
- mHSPC – Metastatic hormone-sensitive prostate cancer
- CAIX – carbonic anhydrase IX
- ccRCC – clear cell renal cell carcinoma
- Bone mets – bone metastases
- LAT1 – L-type amino acid transporter 1
- GBM – glioblastoma multiforme
- LMD – leptomeningeal disease
- CD66 – cluster of differentiation 66
- AML – acute myeloid leukaemia
- FAP – fibroblast activation protein
- PDGFRα – platelet-derived growth factor receptor alpha
- STS – soft tissue sarcoma